enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Medical uses of bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

   Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

3. Apalutamide - Wikipedia

   en.wikipedia.org/wiki/Apalutamide

   Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. [8] [9] [10] [15] It is the first medication to be approved specifically for the treatment of non-metastatic castration-resistant prostate cancer. [2] [10] [9]

4. Side effects of bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Side_effects_of_bicalutamide

   General side effects of bicalutamide that may occur in either sex include diarrhea, constipation, abdominal pain, nausea, dry skin, itching, and rash. In men with prostate cancer, bicalutamide monotherapy has been found to increase the likelihood of death due to causes other than prostate cancer.

5. Galeterone - Wikipedia

   en.wikipedia.org/wiki/Galeterone

   Galeterone (developmental code names TOK-001, VN/124-1) is a steroidal antiandrogen which was under development by Tokai Pharmaceuticals for the treatment of prostate cancer. [1] It possesses a unique triple mechanism of action , acting as an androgen receptor antagonist , androgen receptor down regulator, [ 2 ] and CYP17A1 inhibitor , [ 3 ...

6. Nonsteroidal antiandrogen - Wikipedia

   en.wikipedia.org/wiki/Nonsteroidal_antiandrogen

   Nilutamide (Anandron, Nilandron): Marketed for the treatment of prostate cancer. [3] Very little-used due to a high incidence of interstitial pneumonitis and high rates of several unique and unfavorable side effects such as nausea and vomiting, visual disturbances, and alcohol intolerance.

7. Proxalutamide - Wikipedia

   en.wikipedia.org/wiki/Proxalutamide

   Proxalutamide (developmental code name GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of COVID-19, prostate cancer, and breast cancer.